These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 32384147)
1. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Morris CR; Brown LAS; Reynolds M; Dampier CD; Lane PA; Watt A; Kumari P; Harris F; Manoranjithan S; Mendis RD; Figueroa J; Shiva S Blood; 2020 Sep; 136(12):1402-1406. PubMed ID: 32384147 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD). Tanabe P; Silva S; Bosworth HB; Crawford R; Paice JA; Richardson LD; Miller CN; Glassberg J Am J Hematol; 2018 Feb; 93(2):159-168. PubMed ID: 29047145 [TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Morris CR; Kuypers FA; Lavrisha L; Ansari M; Sweeters N; Stewart M; Gildengorin G; Neumayr L; Vichinsky EP Haematologica; 2013 Sep; 98(9):1375-82. PubMed ID: 23645695 [TBL] [Abstract][Full Text] [Related]
5. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274 [TBL] [Abstract][Full Text] [Related]
6. Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. Kavanagh PL; Sprinz PG; Wolfgang TL; Killius K; Champigny M; Sobota A; Dorfman D; Barry K; Miner R; Moses JM Pediatrics; 2015 Oct; 136(4):e1016-25. PubMed ID: 26391933 [TBL] [Abstract][Full Text] [Related]
7. Management of vaso-occlusive episodes in the day hospital decreases admissions in children with sickle cell disease. Karkoska K; Appiah-Kubi A; Rocker J; Stoffels G; Aygun B Br J Haematol; 2019 Sep; 186(6):855-860. PubMed ID: 31148158 [TBL] [Abstract][Full Text] [Related]
8. Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease. Harris EM; Vilk E; Donado C; Williams A; Heeney MM; Solodiuk J; Greco C; Archer NM Pediatr Blood Cancer; 2023 May; 70(5):e30254. PubMed ID: 36861789 [TBL] [Abstract][Full Text] [Related]
9. Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. Carden MA; Brousseau DC; Ahmad FA; Bennett J; Bhatt S; Bogie A; Brown K; Casper TC; Chapman LL; Chumpitazi CE; Cohen D; Dampier C; Ellison AM; Grasemann H; Hickey RW; Hsu LL; Leibovich S; Powell E; Richards R; Sarnaik S; Weiner DL; Morris CR; Am J Hematol; 2019 Jun; 94(6):689-696. PubMed ID: 30916794 [TBL] [Abstract][Full Text] [Related]